in

Top Influencers: 57 UK Chief Scientific Officer’s To Follow in 2022

Co Founder and Chief Scientific Officer play a crucial role in any startup. It takes an extraordinary person to fulfil the Co Founder and Chief Scientific Officer role. We have selected these Co Founder and Chief Scientific Officer’s for this list as they are inspiring for a variety of reasons – whether that’s pushing boundaries, creating groundbreaking products, or doing their bit to save the world.

Our analysts did their best to select be best, and most innovative Co Founder and Chief Scientific Officer’s. The list is in no particular order!

Table of Contents show

Charles Nduka

Co Founder and Chief Scientific Officer @ Emteq

FollowCharles Nduka on Facebook, Twitter or Linkedin.

Spoiler title
Charles Nduka studied medicine at Oxford University, where he also undertook an undergraduate intercalated degree on Physiological Sciences. He completed his clinical studies for the MB BS degree at St. Mary’s Hospital, in London. He graduated as a doctor in 1994 with a Distinction in Surgery. He was also awarded Honours in Surgery by the University of London. Following his internship he spent 2 years in full-time research with Professor Sir Ara Darzi at Imperial College in the Department of Biosurgery and Surgical Technology. For his thesis on he was awarded a doctoral degree (MD, Doctor of Medicine) by the University of London. He undertook his surgical training in London teaching Hospitals including the Royal London & St Bartholomew’s Hospital, Charing Cross and Hammersmith Hospitals. He completed his specialist training at the Royal Marsden Hospital. He was awarded the Macgregor Gold Medal for his performance in the plastic and reconstructive surgery FRCS examination. Charles has a long track record of R &D and has worked with industrial partners on clinical trials, technology evaluations or as a consultant for 20 years. Previous collaborators include Glaxo-Smithkline, 3DmD, Allergan, ICN, Johnson and Johnson. He has won numerous research awards including from the Wellcome Trust, the National Institute for Health Research, Innovate UK and the Nominet Trust. He is an internationally recognised specialist in facial muscle disorders and in 2007 established the largest unit treating facial paralysis in the UK at the Queen Victoria Hospital. He has multiple patents pending. In 2013 he identified the potential of wearable sensors for monitoring facial muscle activity and funded the development of prototype sensors and proof of concept technologies. He has taken a sabbatical from his full-time clinical role at Queen Victoria Hospital in order to focus on Emteq and develop further IP and products. Learn more about Charles Nduka on Crunchbase…

The world’s first emotion recognition and analysis platform in smart glasses Read more aboutEmteq on Crunchbase…

Amit Nathwani

Founder & Chief Scientific Officer @ Freeline

FollowAmit Nathwani on Facebook, Twitter or Linkedin.

Spoiler title
Amit is renowned for his pioneering work on gene therapy for haemophilia B, and was first to show successful correction of bleeding diathesis in patients with severe haemophilia B. Amit is the Director of the Katharine Dormandy Haemophilia Centre at the Royal Free Hospital, and a Senior NIHR Investigator. He is also Professor of Haematology at UCL. He graduated in Medicine from the University of Aberdeen in 1984. In 1997 he moved to St. Jude Children’s Research Hospital, Memphis, USA, to work with Dr Arthur Nienhuis on adeno-associated virus mediated gene transfer. Here he started his pioneering work on gene therapy for haemophilia B. In 2001 he returned to University College London as a Senior Lecturer in Haematology and a Consultant to the National Blood Services in the UK. He was the first to show successful correction of bleeding diathesis in patients with severe haemophilia B, using a distinct gene transfer approach developed in collaboration with Dr’s Davidoff and Nienhuis at St Jude Children’s Research Hospital. Learn more about Amit Nathwani on Crunchbase…

Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases. Read more aboutFreeline on Crunchbase…

Harish Bhaskaran

Co-Founder & Chief Scientific Officer @ Bodle Technologies

FollowHarish Bhaskaran on Facebook, Twitter or Linkedin.

Spoiler title
Harish is the academic founder of Bodle Technologies (with Peiman) and serves as its Director and Chief Scientific Officer, acting also as its founding executive until Jan 2016. He is an Associate Professor of Materials at the University of Oxford, where he leads the Advanced Nanoscale Engineering Group. A former researcher at IBM Research, Harish has worked in both industry and academia over the past 15 years, including in product development under joint development agreements. His research has most recently focused on novel applications of phase change materials and on the manufacturing of nanoscale components. Learn more about Harish Bhaskaran on Crunchbase…

Developing SRD® technology for a low-power display of vivid colours that doesn’t look washed out in bright conditions Read more aboutBodle Technologies on Crunchbase…

Constantin Coussios

Founder & Chief Scientific Officer @ OxSonics Therapeutics

FollowConstantin Coussios on Facebook, Twitter or Linkedin.

Spoiler title
Professor Constantin holds BA, MEng, MA and PhD degrees in Engineering from the University of Cambridge, and was elected to the first statutory chair in Biomedical Engineering at the University of Oxford in 2011, where he serves as the Director of the Institute of Biomedical Engineering. He is the author of over 100 peer-reviewed publications and 16 patents in the fields of drug delivery, acoustic cavitation and therapeutic ultrasound. Prof. Coussios received the UK’s Institute of Acoustics’ Young Person’s Award for Innovation in Acoustical Engineering in 2007, was elected as Secretary-General of the International Society for Therapeutic Ultrasound between 2006-2010 and was honoured with the Society’s Fred Lizzi award in 2012. He was elected as the youngest ever Fellow of the Acoustical Society of America in 2009 for contributions to biomedical ultrasound, and received the Society’s Bruce Lindsay award in 2012. Prof. Coussios leads the company’s technical development programmes. Learn more about Constantin Coussios on Crunchbase…

OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran® Read more aboutOxSonics Therapeutics on Crunchbase…

Julian Shapley

Chief Scientific Officer and Founder @ CellNovo

FollowJulian Shapley on Facebook, Twitter or Linkedin.

Spoiler title
Dr. Shapley has a cross-functional engineering and scientific background, specialising in Microsystems for drug discovery. Dr Shapley worked with the International Space School at NASA in Houston, Texas. He is also the inventor of Cellnovo’s unique pump technology which serves as the cornerstone of the Cellnovo Mobile Diabetes Management System. Learn more about Julian Shapley on Crunchbase…

Read more aboutCellNovo on Crunchbase…

Tuomas Knowles

Founder and Chief Scientific Officer @ Fluidic Analytics

FollowTuomas Knowles on Facebook, Twitter or Linkedin.

Spoiler title
Professor Tuomas Knowles holds a personal Professorship in the Department of Chemistry at the University of Cambridge and is also a Fellow of St John’s College Cambridge. Tuomas received his PhD in Physics from the University of Cambridge, and has held positions in Engineering in Cambridge and Harvard University before returning to Cambridge as a University Lecturer in 2010, Reader in 2013 and then Professor in 2015. His current research interests are focused on using physical approaches to study the self-assembly of protein molecules both in the context of disease and for the synthesis of novel functional biomaterials. Tuomas has received a number of distinguished awards, most recently from the Royal Society of Chemistry, the Newman Foundation and the European Research Council, and has co-authored over 60 peer-reviewed scientific articles. Learn more about Tuomas Knowles on Crunchbase…

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised. Read more aboutFluidic Analytics on Crunchbase…

Clement Champion

Co-Founder and Chief Scientific Officer @ MoA Technology Ltd

FollowClement Champion on Facebook, Twitter or Linkedin.

Spoiler title
Clément graduated from the French Grandes Écoles with an Engineer’s degree in Agronomy before moving to Oxford in 2012. He was awarded a Clarendon scholarship to work on the genetic control of plant growth in Prof. Dolan’s research group. After completing his D. Phil, Clément contributed to the conception of MoA Technology’s discovery platforms and has since been leading the biology research group. Learn more about Clement Champion on Crunchbase…

MoA Technology Ltd has developed an innovative approach for the discovery of agricultural technologies. Read more aboutMoA Technology Ltd on Crunchbase…

David O’Rourke

Co-Founder and Chief Scientific Officer (CSO) & Chief Innovation Officer (CIO) @ Bea Fertility

FollowDavid O’Rourke on Facebook, Twitter or Linkedin.

Spoiler title
David O’Rourke is the Chief Operating Officer and Co-Founder of Bea Fertility. Learn more about David O’Rourke on Crunchbase…

Bea Fertility is a monthly subscription program that provides users with at-home fertility treatment and ovulation tracking. Read more aboutBea Fertility on Crunchbase…

Ashwin Seshia

Co-Founder & Chief Scientific Officer @ Silicon MicroGravity

FollowAshwin Seshia on Facebook, Twitter or Linkedin.

Spoiler title
Ashwin Seshia is the Co-Founder, Chief Scientific Officer and a Member of the Board of Directors at Silicon Microgravity since September 2014. Silicon Microgravity was formed to commercialise the academic work pioneered by Ashwin. Ashwin joined the faculty of the Engineering Department at the University of Cambridge in October 2002 where he is presently a Reader in Microsystems Technology and a Fellow of Queens’ College. Ashwin is a Fellow of the Institute of Physics, a Fellow of the Institution for Engineering and Technology and a senior member of the Institute of Electrical and Electronics Engineers. Ashwin’s research interests are in the domain of micro-engineered dynamical systems with applications to sensors and sensor systems. Ashwin received his B.Tech. degree in Engineering Physics in 1996 from Indian Institute of Technology, Mumbai, M.S. and Ph.D. degrees in Electrical Engineering and Computer Sciences from the University of California, Berkeley in 1999 and 2002 respectively and the M.A. degree from the University of Cambridge in 2008. During his time at the University of California, Berkeley, Ashwin was affiliated with the Berkeley Sensor & Actuator Center. Learn more about Ashwin Seshia on Crunchbase…

Silicon MicroGravity is a company developing novel sensor technology. Read more aboutSilicon MicroGravity on Crunchbase…

Nirmesh Patel

Co-Founder and Chief Scientific Officer @ Cambridge Cancer Genomics

FollowNirmesh Patel on Facebook, Twitter or Linkedin.

Spoiler title
Nirmesh spearheads the clinical research and establishes experimental developments at CCG, sitting at the interface between clinical collaborators and the lab. He brings a deep understanding of the clinical applications of cancer biology, with a background in translational cancer medicine and novel therapeutic development through his PhD at King’s College London and the Institute of Cancer Research. Learn more about Nirmesh Patel on Crunchbase…

Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated. Read more aboutCambridge Cancer Genomics on Crunchbase…

Trevor Lawley

Co-Founder and Chief Scientific Officer @ Microbiotica

FollowTrevor Lawley on Facebook, Twitter or Linkedin.

Hello Twitter friends, we are recruiting a post doc to the Lawley Lab (http://www.lawleylab.com) work on gut microbiome metabolism of early life bacteria and want to spread the word....link below...please retweet...

https://www.nature.com/naturecareers/job/postdoctoral-fellowmicrobial-metabolism-in-earlylife-human-microbiota-wellcome-sanger-institute-763628

Spoiler title
Trevor Lawley is a co-founder and Chief Scientific Officer of Microbiotica. He is also Faculty Group Leader of the Host-Microbiota Interactions Team at the Wellcome Trust Sanger Institute (WTSI), where his research uses advanced metagenomic sequencing and deep culturing to investigate the microbial communities contained on and within host organisms that are associated with health and a range of diseases and syndromes such as infections, autoimmunity, irritable bowel syndromes and cancer. He has pioneered many aspects of the bacteriotherapy concept where defined mixtures of bacteria are used to cure intestinal diseases linked to pathological imbalances in the intestinal microbiota. Trevor began his research at WTSI in 2007 as a Post-Doctoral Fellow in the Microbial Pathogenesis group, having received a Royal Society Fellowship to start a new research programme in C. difficile epidemiology and pathogenesis. During this time, he has worked with a global consortium from over 25 institutes to assemble a comprehensive C. difficile culture collection, now housed within the Sanger Institute. Prior to joining WTSI, Trevor held a Canadian Institutes of Health Research post-doctoral fellowship, working in the Laboratory of Professor Stanley Falkow and Dr Denise Monack at Stanford University, USA, where he studied the impact of antibiotic treatment on Salmonella disease and transmission. Trevor gained his first degree from Acadia University, Canada and his PhD from the University of Alberta, Canada, where he pioneered the use of genomics to study the origins and spread of antibiotic resistance in infectious diseases. He received the Canadian Society of Microbiologists Graduate Student of the Year Award for this work. More recently, Trevor was recognised by the Peggy Lillis Foundation with their Innovator Award 2015 for his ground-breaking work on developing bacteriotherapy for C. difficile infections. Learn more about Trevor Lawley on Crunchbase…

Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. Read more aboutMicrobiotica on Crunchbase…

Barbara Mertins

Chief Scientific Officer @ ExcepGen

FollowBarbara Mertins on Facebook, Twitter or Linkedin.

Spoiler title
Barbara received her PhD (Dr. rer. nat.) in Biochemistry from the Philipps University of Marburg in Germany. She then joined the University of Oxford as a Postdoctoral Research Associate, studying the structural biology of complex membrane proteins. After her postdoctoral research, Barbara worked as a Senior Scientist at Evotec, a contract drug development company. Her time at Evotec gave her deeper insights into the challenges of protein production in drug discovery. Learn more about Barbara Mertins on Crunchbase…

Read more aboutExcepGen on Crunchbase…

Nick Lench

Chief Operating Officer & Chief Scientific Officer @ Congenica

FollowNick Lench on Facebook, Twitter or Linkedin.

We’re looking forward to the @SAEMGPharma #Oligonucleotide #Therapeutics and #Delivery Conference & Workshop in London, 20–22 Sep. Come and talk to us to find out more about what we do and how we can partner with you: http://www.natahub.org/news #OligoTx #NucleicAcidTherapies

Spoiler title
Nick was previously Director of the NE Thames Regional Genetics Service at Great Ormond Street Hospital for Children, London, with responsibility for the strategic and operational management of a genetics service that provides DNA diagnostic testing to a population of approximately 4.5M people. Nick is an honorary Reader at the UCL Institute of Child Health, London and has over 25 years of research experience in human molecular genetics and was awarded a personal chair in Medical Genetics at Cardiff University in 2005. As founding CEO of London Genetics Ltd and Programme Director at Oxagen Ltd, Nick has gained significant expertise in establishing and managing academic, healthcare and commercial partnerships in biomedical discovery and diagnostics. Learn more about Nick Lench on Crunchbase…

Congenica is a biotechnology company that provides a diagnostic decision support platform. Read more aboutCongenica on Crunchbase…

Iva Navratilova

Founder and Chief Scientific Officer @ Kinetic Discovery Ltd.

FollowIva Navratilova on Facebook, Twitter or Linkedin.

Spoiler title
Dr Iva Navratilova has over 17 years experience in biosensor technology development and is the pioneer of the application of SPR screening methods for membrane proteins. Learn more about Iva Navratilova on Crunchbase…

Kinetic Discovery Ltd offers drug discovery services as hit identification, confirmation and validation. Read more aboutKinetic Discovery Ltd. on Crunchbase…

Mick Hunter

Chief Scientific Officer & Director of Development @ Atopix Therapeutics

FollowMick Hunter on Facebook, Twitter or Linkedin.

Spoiler title
Dr Mick Hunter has responsibility for drug discovery and development in Atopix. He has over 28 years experience in Pharmaceutical and Biotech R&D. He has spent the past 12 years working on the discovery and development of antinflammatory and respiratory drugs. He is also Director of Discovery at Oxagen Ltd. Mick has led Atopix CRTH2 antagonist discovery and development program from concept to Phase IIb. Less Mick has experience of leading teams to identify IND candidates and managing them through early clinical development. He is familiar with regulatory environments and has managed biological pilot plants for GMP manufacture. Prior to joining Atopix, Mick held positions at Oxagen Ltd, British Biotech Pharmaceuticals (now Vernalis PLC) and at Searle Pharmaceuticals. Learn more about Mick Hunter on Crunchbase…

Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK Read more aboutAtopix Therapeutics on Crunchbase…

Pankaj Vadgama

Founder & Chief Scientific Officer @ Camstech

FollowPankaj Vadgama on Facebook, Twitter or Linkedin.

Spoiler title
Professor Pankaj Vadgama qualified in Medicine and Chemistry. He is Professor of Clinical Biochemistry and recently, Director of the Interdisciplinary Research Centre in Biomedical Materials, at Queen Mary University of London. His interests are in electrochemical biosensors for near-patient and in vivo monitoring, using miniaturised sensors and microdialysis. He has adapted biosensor chemistry for direct operation in biofluids and tissue, and has over 200 publications, 20 published patents. His underpinning research is in membrane technology for device packaging, and he was one of the first to report diffusion control membranes for extended linear range enzyme electrodes. He has variously worked on spider silk as an implant material, microfluidics for diagnostics, electrochemical characterisation of bone adhesives and is currently working on biodegradable sensors and on nanosilver as an antimicrobial for urine catheters. His has recently established a sensors spinout company, Camstech Ltd., to develop optical sensors Learn more about Pankaj Vadgama on Crunchbase…

Camstech develops novel sensing technology used for point-of-care diagnostics. Read more aboutCamstech on Crunchbase…

Mike Trower

Founder, Chief Scientific Officer & Chief Operating Officer @ NeRRe Therapeutics

FollowMike Trower on Facebook, Twitter or Linkedin.

Spoiler title
Mike is Co-founder and Chief Scientific Officer of KaNDy Therapeutics. It was Mike’s advocacy of the dual mechanism neurokinin-1,3 receptor antagonism, offered by NT-814, to present a novel and potentially transformational non-hormonal therapy for treatment of symptoms of the menopause and other related Women’s Health conditions which led to NT-814 being spun out of NeRRe Therapeutics to create KaNDy Therapeutics in 2017. Mike has broad knowledge of neurokinin receptor biology and, in particular, the emerging science that has established the pivotal role these systems play in neuroendocrinology and female sex-hormone related disorders. Mike is also Co-founder and CSO of NeRRe Therapeutics whose focus is on developing the neurokinin-1 receptor antagonist orvepitant to treat neuronal hypersensitivity disorders including chronic refractory cough. Prior to founding NeRRe, Mike worked in pharmaceutical industry R&D at GSK for nearly 20 years, where latterly he was VP & Head of the External Drug Discovery Group in the Neurosciences Centre for Excellence for Drug Discovery (CEDD). In this position, Mike successfully implemented the CEDD externalisation strategy and advanced a portfolio of preclinical and clinical pipeline assets. Mike has BSc (Hons) and PhD degrees in biological sciences and has held post-doctoral positions at DuPont Inc in Delaware, US, and at the Medical Research Council in Cambridge, UK, under the Nobel laureate Professor Sydney Brenner. Learn more about Mike Trower on Crunchbase…

NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. Read more aboutNeRRe Therapeutics on Crunchbase…

Kevin FitzGerald

Chief Scientific Officer @ Epsilogen

FollowKevin FitzGerald on Facebook, Twitter or Linkedin.

Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer. Read more aboutEpsilogen on Crunchbase…

Dr. James Clark

Chief Scientific Officer @ HigherSteaks

FollowDr. James Clark on Facebook, Twitter or Linkedin.

Spoiler title
Dr. James Clark is the Chief Scientific Officer of HigherSteaks. He brings over 25 years of experience in biotechnology, development, and commercialization experience to Higher Steaks. Dr. Clark is a former Chief Technical Officer at Predict Immune and Chief Executive Office of Enterobiotix (development and commercialization of an MHRA regulated Faecal Microbial Transplant(FMT) product). Learn more about Dr. James Clark on Crunchbase…

HigherSteaks is about providing with that juicy, tender, and delicious meat they love but without harming their health, planet, and animals. Read more aboutHigherSteaks on Crunchbase…

Brian Champion

Chief Scientific Officer @ Psioxus Therapeutics

FollowBrian Champion on Facebook, Twitter or Linkedin.

Spoiler title
Dr Brian Champion was previously Executive Director and Head of Immunology for Pfizer’s Vaccine Immunotherapeutics Research Unit in La Jolla, California. In this role Brian led the immunology team providing expertise and immunoassays for all Pfizer vaccine projects, including therapeutic T-cell focused vaccines for cancer, antibody focused vaccines for several different diseases as well as several prophylactic infectious disease vaccines. He was also a member of the leadership team as well as Program Lead for an anti-IgE therapeutic vaccine for allergy/asthma. Prior to this role, Brian was Site Head for Pfizer Vaccine Research in the UK. Before joining Pfizer, Dr Champion was Chief Scientific Officer for Lorantis and Celldex, Cambridge, developing protein and DNA-based, antigen-specific immunotherapeutic approaches to a variety of immunological diseases, including therapeutic vaccines and immunotherapeutic biomolecule approaches for cancer, infectious diseases, allergies and autoimmune disorders. Prior to Lorantis, he was with Glaxo and GlaxoWellcome (UK and USA) for 13 years, focusing primarily on target discovery and validation research for autoimmune, allergic and bone disorders. Learn more about Brian Champion on Crunchbase…

Psioxus Therapeutics is a cancer gene therapy company delivers medicines of value to patients with cancer. Read more aboutPsioxus Therapeutics on Crunchbase…

Dapeng Yu

Founder and Chief Scientific Officer @ Previsico

FollowDapeng Yu on Facebook, Twitter or Linkedin.

Spoiler title
Dapeng Yu is a Professor of River Dynamics at Loughborough University. He is the founder and Chief Scientific Officer of Previsico. Learn more about Dapeng Yu on Crunchbase…

Previsico is a global provider of real-time, street level flood prediction, and analytical solutions, building round-the-clock resilience. Read more aboutPrevisico on Crunchbase…

John Milton

Chief Scientific Officer @ Oxford Nanopore Technologies

FollowJohn Milton on Facebook, Twitter or Linkedin.

Spoiler title
John is Chief Scientific Officer at Oxford Nanopore. On the Executive team, he has responsibility for all chemical and biological R&D activity within the company and particularly the design and delivery of the company’s nanopore-based sequencing technology. John drives the primary architectural designs of the chemical systems, building a disruptive system ready for launch into the marketplace. John joined Oxford Nanopore from Solexa (2001-2007), where as Senior Director of R&D he designed and built the Reversible Terminator chemistry that now drives the Illumina HiSeq/MiSeq system. He built and managed a large, multi-disciplinary scientific team in areas including synthetic nucleotide chemistry, fluorescence chemistry, photochemistry, enzyme engineering, sample prep and chip surface chemistry. He also drove development of the full sequencing protocols and ultimately the scale-up and production of the sequencing reagents for commercial launch. The scientific work of John’s team was critical to the achievement of early sequence data that progressed to other major sequencing milestones and ultimately a full human genome. Solexa was sold to Illumina for $650m in 2007 after the successful placement of 12 instruments, and the Illumina systems are now considered the market leader. Earlier in his career, following his Ph.D in Chemistry (Liverpool) and two year post doctoral work (Leeds), John held various scientific and management positions in Medicinal Chemistry firstly at GlaxoWellcome (four years) then at Xenova (four years), where he specialized in designing new chemical systems that interact with the biological machinery of genetic processing with applications as antiviral and anti-cancer therapeutics. Learn more about John Milton on Crunchbase…

Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins. Read more aboutOxford Nanopore Technologies on Crunchbase…

Stuart Cockerill

Founder and Chief Scientific Officer @ ReViral

FollowStuart Cockerill on Facebook, Twitter or Linkedin.

Spoiler title
Stuart Cockerill PhD Chief Scientific Officer, Founder Stuart was the Principal Investigator on a Wellcome Trust funded Project, on behalf of ReViral. He obtained his PhD in Organic Chemistry at the University of Leeds. After a Postdoctoral fellowship at Cornell University, he joined the GSK heritage company, the Wellcome Foundation and over the next 15 years led drug discovery projects in Pesticides, Immunology, Virology and Oncology. His key achievement was leading the erbB2 Oncology Project Team that discovered Tykerb™ for which Stuart is a named inventor. In December 2000, Stuart joined Arrow Therapeutics as Head of Chemistry and subsequently as Research Director. Stuart remained as Head of Arrow until the end of 2010. Stuart held the position of Senior Lecturer in Medicinal Chemistry at the University of Durham. His key achievements were two clinical Proof of Concept drug candidates involving novel approaches to the treatment of Respiratory Syncytial Virus and Hepatitis C Virus infection. Stuart is an author of over 70 papers, patents and book chapters. Learn more about Stuart Cockerill on Crunchbase…

ReViral is a biotechnology company that develops and offers antiviral therapies for patients. Read more aboutReViral on Crunchbase…

Charalambos Antoniades

Founder and Chief Scientific Officer @ Caristo Diagnostics

FollowCharalambos Antoniades on Facebook, Twitter or Linkedin.

Caristo Diagnostics utilises standard CT scans to identify potentially heart-stopping plaques Read more aboutCaristo Diagnostics on Crunchbase…

Henry Snaith

Chief Scientific Officer & Co-Founder @ Oxford PV

FollowHenry Snaith on Facebook, Twitter or Linkedin.

Spoiler title
In December 2010, Professor Henry Snaith co-founded Oxford Photovoltaics to commercialise the solar technology transferred from his laboratory at the University of Oxford. Henry undertook his PhD in organic photovoltaics at the University of Cambridge. Following his PhD, he spent two years at the École Polytechnique Fédérale de Lausanne (EPFL) as a post-doc, where his research focused on developing the technology behind and understanding of the operation of solid-state dye-sensitized solar cells. In 2012, Henry was awarded the Paterson medal and prize by the Institute of Physics for his important contributions to the field of excitonic solar cells. The following year his discovery of high efficiency metal halide perovskite photovoltaics was recognised as one of the top breakthroughs of 2013 by Science. In 2013, Nature named Henry for its list of ten people who mattered, in recognition of his work on next generation solar power technology and was one of the youngest ever elected Fellow of The Royal Society in 2015. In 2017, he was named a Clarivate Citation Laureate and in 2018 he received the UK Blavatnik Awards Laureate in physical sciences. In addition to his role as Chief Scientific Officer at Oxford PV today, Henry also leads the Photovoltaics and Optoelectronics Device Group at the University of Oxford. Learn more about Henry Snaith on Crunchbase…

Oxford PV is a provider of perovskite solar cells. Read more aboutOxford PV on Crunchbase…

Graeme Smith

Chief Scientific Officer @ Artios Pharma

FollowGraeme Smith on Facebook, Twitter or Linkedin.

Spoiler title
Graeme has more than 25 years’ experience in oncology research, with significant expertise and in-depth knowledge in the field of DDR. He joins Artios from AstraZeneca, where he held the position of Senior Director of Bioscience within the Oncology Innovative Medicines and Early Development (IMED) division. In this role, Graeme was responsible for leading a group of approximately 100 bioscientists in target validation and the discovery and development of novel anti-cancer agents. Prior to joining AstraZeneca, he was Head and Research Director at KuDOS Pharmaceuticals where he played a key role in the discovery and development of Lynparza™ (olaparib), the first targeted DDR inhibitor to reach the market. Graeme gained his PhD from the University of Edinburgh and subsequently worked as a Research Fellow at the Wellcome/CRC Institute at the University of Cambridge in the laboratory of Professor Steve Jackson, FRS. Learn more about Graeme Smith on Crunchbase…

Artios Pharma is a independent DNA Damage Response company with a strong pipeline of novel cancer therapies. Read more aboutArtios Pharma on Crunchbase…

Craig Fox

Chief Scientific Officer @ C4X Discovery

FollowCraig Fox on Facebook, Twitter or Linkedin.

Spoiler title
Craig is an experienced biologist having worked on and managed many drug discovery and development projects during the last 18 years, from initial target selection right through to investigating clinical efficacy and safety in Ph II patient studies. Prior to joining C4X Discovery, Craig was director of Respiratory Research at Pulmagen Therapeutics, a clinical stage company spun-out of Argenta in 2010. Craig was part of the Etiologics Team that merged with Argenta Discovery in 2004 and prior to this he worked for Bayer as a Research Scientist. Craig has a PhD from Birmingham University and a first class biochemistry degree from the University of Surrey. Learn more about Craig Fox on Crunchbase…

C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular. Read more aboutC4X Discovery on Crunchbase…

Ali Jazayeri

Chief Scientific Officer @ OMass Technologies

FollowAli Jazayeri on Facebook, Twitter or Linkedin.

Spoiler title
Ali Jazayeri joined OMass Therapeutics in October 2018. He was previously Chief Technology Officer of Heptares Therapeutics, a company he joined in 2007 as one of the first scientists and was involved in the transfer of the GPCR stabilisation technology from the MRC Laboratory of Molecular Biology to Heptares. Following successful implementation and industrialisation of the original technology, he led the development of novel methodologies that significantly increased the efficiency and reach of the technology and resulted in the generation of novel IP. In addition, he was one of the key members of the executive sub-team that lead the acquisition of G7 therapeutics, spin out company from University of Zurich and went on to lead the further development and integration of their technology as part of the Heptares Zurich management team. Prior to Heptares, Ali worked as a post-doctoral scientist in Clare Hall Laboratories (a Cancer Research UK institute) and Kudos Pharmaceuticals (later acquired by AstraZeneca) where he carried out research on the role of cell cycle checkpoint kinases in DNA damage response pathways. He has a BSc in Genetics from University of Manchester and obtained his PhD in molecular biology with Prof Steve Jackson at the Gurdon Institute from University of Cambridge. Learn more about Ali Jazayeri on Crunchbase…

OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics. Read more aboutOMass Technologies on Crunchbase…

Conor Barry

CSO (Chief Scientific Officer) @ EnzBond

FollowConor Barry on Facebook, Twitter or Linkedin.

In-silico development of enzymes for pharma Read more aboutEnzBond on Crunchbase…

Ramunas Janavicius

Chief Scientific Officer @ Advisor.Clinic

FollowRamunas Janavicius on Facebook, Twitter or Linkedin.

Advisor.Clinic provides advice on reproductive health to future parents. Read more aboutAdvisor.Clinic on Crunchbase…

Jutta Roth

Chief Scientific Officer @ Oxford Cannabinoid Technologies

FollowJutta Roth on Facebook, Twitter or Linkedin.

Spoiler title
Jutta is responsible for driving the research strategy and IP development of OCT. With over fifteen years’ experience, Jutta previously served as Head of Strategic Development for Barts and The London School of Medicine and as Director of Partnerships for the Centre for Population Genomic Medicine in London, a collaboration between University College London, King’s College London and Queen Mary University of London. Having researched the potential of cannabinoids during her time at the University of Oxford, Jutta joined OCT to bring together academic and industry research in a competitive research programme. Jutta has worked on various model organisms and has experience in a number of disease areas, including cardiovascular disorders, rare disorders, women’s health, and neuroscience. A published academic researcher, Jutta holds a PhD in Genetics with Distinction, and an MSc in microbiology, both from the University of Salzburg, with later research fellowships at Yale University and the National Institute for Medical Research. Learn more about Jutta Roth on Crunchbase…

OCT is a biopharmaceutical company established to combine cannabinoid medicine with world class scientific research. Read more aboutOxford Cannabinoid Technologies on Crunchbase…

Catherine O’Neill

Chief Scientific Officer @ SkinBioTherapeutics plc

FollowCatherine O’Neill on Facebook, Twitter or Linkedin.

Spoiler title
Cath is an accomplished biologist and a leader in human-bacterial interactions. Cath previously founded a specialist dermatology business, Curapel Limited, leading the company through its formation and development stage. As an innovator and expert Cath has worked as an advisor for a number of skincare businesses and brand owners. This includes delivering technology from the lab, through development and onto to new product concepts in partnership with global corporations. Cath is a biochemist by training and has previously led research teams as a senior lecturer at the University of Manchester. Learn more about Catherine O’Neill on Crunchbase…

Developing and commercialising its SkinBiotix technology platform Read more aboutSkinBioTherapeutics plc on Crunchbase…

Allan Bradley

Chief Scientific Officer @ Kymab

FollowAllan Bradley on Facebook, Twitter or Linkedin.

Spoiler title
Professor Bradley completed his PhD studies in genetics at the University of Cambridge in 1984. Working with Liz Robertson in the laboratory of Martin Evans, who shared the Nobel Prize for Physiology or Medicine in 2007, they showed that embryonic stem cells could be used to stably modify mouse genes. In 1987 Professor Bradley moved to Baylor College of Medicine, Houston, Texas, where his laboratory developed novel methods to engineer the genomes of mice. He was appointed Investigator with the Howard Hughes Medical Institute in 1993 and full Professor in 1994. In 2000, Dr Bradley returned to the UK as Director of the Welcome Trust Sanger Institute. Learn more about Allan Bradley on Crunchbase…

Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics. Read more aboutKymab on Crunchbase…

James Phillips

Chief Scientific Officer @ Glialign

FollowJames Phillips on Facebook, Twitter or Linkedin.

Spoiler title
James Phillips is Reader in Regenerative Medicine at University College London (UCL). He runs a research group based at the UCL School of Pharmacy, is co-Director of the UCL Centre for Nerve Engineering and Vice-Dean (Innovation & Enterprise) for the UCL Faculty of Life Sciences. His previous role was Senior Lecturer in Biomaterials & Tissue Engineering at UCL and before that he was Lecturer in Health Sciences at the Open University. After a first degree in Biochemistry at Imperial College London (awarded 1996), James completed his PhD in Pharmacology at the School of Pharmacy, University of London (awarded 2000). He was a Postdoctoral Researcher in the Tissue Repair and Engineering Centre at UCL, then worked as a Research Fellow in the Surgery Department at UCL. James is currently involved in a range of research projects including collaborations with scientists, clinicians and engineers working in academia, industry and healthcare. He is a member of the Editorial Board for the Journal of Biomaterials Applications, part of the Executive Committee of the Tissue and Cell Engineering Society and a Board Member for the European Society for the Study of Peripheral Nerve Repair and Regeneration. Learn more about James Phillips on Crunchbase…

Glialign is developing a novel cell therapy for peripheral nerve repair. Read more aboutGlialign on Crunchbase…

Nigel Walshe

Chief Scientific Officer @ Chalante

FollowNigel Walshe on Facebook, Twitter or Linkedin.

Spoiler title
Nigel has thirty years of experience in the Animal Health sector, working in R&D at Pfizer Animal Health (now Zoetis) at Sandwich in the UK. Nigel has worked in many therapeutic areas in the veterinary sector, including antiprotozoals, pain and inflammation, performance enhancement, and with a particular focus on antiparasitic treatments for livestock and companion animals. A synthetic chemist by training, he has a strong focus on natural products, and as such, has been involved in the discovery and development of products such as Aviax™, a polyether ionophore for prevention of coccidiosis in poultry, the cattle endectocide Dectomax™, the pet endectocide Revolution™, and recently in the development of a novel cattle antiparasitic Treo Ace™ launched in the Brazil sector. Learn more about Nigel Walshe on Crunchbase…

Chalante serves as an external source of innovation to support animal health, animal well-being and performance. Read more aboutChalante on Crunchbase…

Emanuele Paci

Chief Scientific Officer @ Peptone

FollowEmanuele Paci on Facebook, Twitter or Linkedin.

Peptone is a UK-based startup that is helping pharmaceutical companies unravel the secrets of proteins. Read more aboutPeptone on Crunchbase…

Dave Snowden

Founder & Chief Scientific Officer @ Cognitive Edge

FollowDave Snowden on Facebook, Twitter or Linkedin.

My general experience is that when people start out with a claim that they will make things ‘simple’ it means simplistic and generally means their understanding (especially of implications) is sketchy. Good communicators just so it, they don’t need the claim

Spoiler title
Dave Snowden is a Founder & Chief Scientific Officer at Cognitive Edge. Learn more about Dave Snowden on Crunchbase…

Read more aboutCognitive Edge on Crunchbase…

David Cook

Chief Scientific Officer @ Blueberry Therapeutics

FollowDavid Cook on Facebook, Twitter or Linkedin.

Blueberry Therapeutics focuses on developing medicines for inflammatory and infectious diseases. Read more aboutBlueberry Therapeutics on Crunchbase…

Miles Houslay

Chief Scientific Officer and Director @ Mironid

FollowMiles Houslay on Facebook, Twitter or Linkedin.

Mironid is a drug discovery company focused on therapeutics for degenerative kidney diseases, chronic inflammatory diseases, and cancer. Read more aboutMironid on Crunchbase…

Mark Gooding

Chief Scientific Officer @ Mirada Medical

FollowMark Gooding on Facebook, Twitter or Linkedin.

Mirada Medical is a prominent global brand in medical imaging software. Mirada’s innovative software solutions are routinely used in Read more aboutMirada Medical on Crunchbase…

Timothy Bourne

Chief Scientific Officer @ Step Pharma

FollowTimothy Bourne on Facebook, Twitter or Linkedin.

Read more aboutStep Pharma on Crunchbase…

Graham Lowe

Chief Operating Officer and Chief Scientific Officer @ Deltex Medical Group

FollowGraham Lowe on Facebook, Twitter or Linkedin.

Deltex Medical Group is a company that specializes in mobile technology for medicine. Read more aboutDeltex Medical Group on Crunchbase…

Lisa Patel

Chief Scientific Officer @ Istesso

FollowLisa Patel on Facebook, Twitter or Linkedin.

Spoiler title
Lisa is CSO and co-founder of Istesso. Prior to joining the company in 2007, she spent 10 years at GlaxoSmithKline as a team leader in the Cardiovascular Centre of Excellence and latterly as a group leader in Clinical Pharmacology and Discovery Medicine. She is a non-executive director of Iksuda Ltd and Apcintex Ltd. Lisa has a PhD in molecular genetics, a degree in biochemistry and an MBA. Learn more about Lisa Patel on Crunchbase…

Istesso is a drug discovery and development company working in the field of immunometabolism. Read more aboutIstesso on Crunchbase…

Natalia Mateu

Chief Scientific Officer @ PharmEnable

FollowNatalia Mateu on Facebook, Twitter or Linkedin.

PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery. Read more aboutPharmEnable on Crunchbase…

Lilian Hook

Chief Scientific Officer @ Smart Matrix

FollowLilian Hook on Facebook, Twitter or Linkedin.

Spoiler title
Lilian Hook has 20 years’ experience in biomedical research, in both industry and academia. In previous roles, has focused primarily on the application of stem cells in drug discovery and regenerative medicine. PhD in Development Biology from the University of Edinburgh. Degree in Natural Sciences from Cambridge University. Learn more about Lilian Hook on Crunchbase…

Smart Matrix is a medical device manufacturing company that specializes in wound care, regenerative medicine, and medical devices. Read more aboutSmart Matrix on Crunchbase…

David Barber

Chief Scientific Officer @ re:infer

FollowDavid Barber on Facebook, Twitter or Linkedin.

Spoiler title
David Barber is reader in information processing in the Department of Computer Science at UCL, where he develops novel machine-learning algorithms. David is also a cofounder of the NLP company reinfer.io. Learn more about David Barber on Crunchbase…

Re:infer is an enterprise intelligence system that makes communications data understood and actionable. Read more aboutre:infer on Crunchbase…

Julie Barnes

Founder/ Chief Scientific Officer & Chief Executive Officer @ Abcodia

FollowJulie Barnes on Facebook, Twitter or Linkedin.

Spoiler title
Julie has over 20 years experience of the Pharmaceutical and Biotechnology industry, including 15 years experience of early R&D with GlaxoSmithKline. More recently Julie was director and Chief Scientific Officer at BioWisdom, a healthcare technology company. Her mix of scientific and commercial experience in large pharmaceutical and small start-ups and academic network brings a strong understanding of what is required to successfully lead Abcodia as an ethical and collaborative organisation. Learn more about Julie Barnes on Crunchbase…

Abcodia is an innovative biotech company engaged in the validation and discovery of molecular biomarkers. Read more aboutAbcodia on Crunchbase…

Jane Osbourn

Co-Founder, Chief Scientific Officer & Chief Technology Officer @ Alchemab Therapeutics

FollowJane Osbourn on Facebook, Twitter or Linkedin.

Spoiler title
Jane Osbourn is the chairman at Mogrify. Learn more about Jane Osbourn on Crunchbase…

Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. Read more aboutAlchemab Therapeutics on Crunchbase…

JEFF NG

Chief Scientific Officer @ Founders Factory

FollowJEFF NG on Facebook, Twitter or Linkedin.

Read more aboutFounders Factory on Crunchbase…

Alan Watt

Chief Scientific Officer @ NodThera

FollowAlan Watt on Facebook, Twitter or Linkedin.

NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases. Read more aboutNodThera on Crunchbase…

Jan Jezek

Chief Scientific Officer @ Arecor

FollowJan Jezek on Facebook, Twitter or Linkedin.

Spoiler title
Jan Jezek joined Arecor as Chief Scientific Officer in 2007. Learn more about Jan Jezek on Crunchbase…

Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Read more aboutArecor on Crunchbase…

Cath Rees

Chief Scientific Officer @ PBD Biotech

FollowCath Rees on Facebook, Twitter or Linkedin.

PBD Biotech specialises in novel phage-based diagnostics for the veterinary, agriculture and human health sectors Read more aboutPBD Biotech on Crunchbase…

Laurence Pearl

Chief Scientific Officer @ Domainex

FollowLaurence Pearl on Facebook, Twitter or Linkedin.

Spoiler title
Laurence Pearl is Professor of Crystallography and Chairman of the Section of Structural Biology at the Institute of Cancer Research, Chester Beatty Laboratories in Chelsea. He began his research career at Birkbeck College working with Sir Tom Blundell, and after postdoctoral research at ICR Sutton, started his own laboratory at UCL in 1989, becoming Professor of Structural Biology in 1996. He joined ICR in 1999, where his laboratory studies the structural biology of DNA repair, signal transduction and molecular chaperones. He is a Trustee of the ICR, a scientific advisor to Abingworth, an elected member of EMBO, a Fellow of the Academy of Medical Sciences, and a Fellow of the Royal Society. Learn more about Laurence Pearl on Crunchbase…

A fully integrated drug discovery service company. Read more aboutDomainex on Crunchbase…

Andrew McNeill

Chief Scientific Officer @ Taragenyx

FollowAndrew McNeill on Facebook, Twitter or Linkedin.

Regenerating orthopedic and dental implant design to help patients heal faster with far less pain. Read more aboutTaragenyx on Crunchbase…

Steven Howdle

Chief Scientific Officer @ Critical Pharmaceuticals

FollowSteven Howdle on Facebook, Twitter or Linkedin.

Spoiler title
Steven Howdle is Founder and Chief Scientific Officer at Critical Pharmaceuticals. He is a world-renowned scientist in the field of supercritical fluid processing with over 15 years experience in the field. Steve holds a Chair of Chemistry at The University of Nottingham and has published over 300 papers in high-level scientific journals. Over the past 10 years his research has focused on the pharmaceutical formulation of drugs using supercritical fluids and he has filed ten patents. Steve has received the Corday Morgan Medal and Award (2001) and Interdisciplinary Award (2005) of the Royal Society of Chemistry, the Jerwood Salters Environment Award (2001), Royal Society/Wolfson Research Merit Award (2003) and the DECHEMA-Award 2006 of the Max Buchner Research Foundation; only the second time this was awarded outside of Germany in the last fifty years. Steve has achieved an H-index of 40 (Web of Science). Learn more about Steven Howdle on Crunchbase…

Critical Pharmaceuticals develops drug delivery technologies for the sustained release and nasal delivery of proteins and small molecules. Read more aboutCritical Pharmaceuticals on Crunchbase…

Martin Everett

Chief Scientific Officer @ Antabio

FollowMartin Everett on Facebook, Twitter or Linkedin.

Spoiler title
Martin Everett is a Chief Scientific Officer at Antabio. He is a former Head of Research at MerLion Pharmaceuticals and Senior Research Scientist at GlaxoWellcome. Mr. Everett graduated from the University of Bristol with a Ph.D. in Molecular genetics of beta-lactamases and earned a bachelor of science in Microbiology at the University of Wales, Swansea. Learn more about Martin Everett on Crunchbase…

Read more aboutAntabio on Crunchbase…

Gary Mckeown

Chief Scientific Officer @ Adoreboard

FollowGary Mckeown on Facebook, Twitter or Linkedin.

Adoreboard is a unique platform that helps brands to understand online customer emotion. Read more aboutAdoreboard on Crunchbase…

This post contains affiliate links. Affiliate disclosure: As an Amazon Associate, we may earn commissions from qualifying purchases from Amazon.com and other Amazon websites.

Top Influencers: 43 UK Chief Revenue Officer’s To Follow in 2022

Top Influencers: 32 UK Co-Founder and COO’s To Follow in 2022